Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accelerated Access Review

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

- PMLiVE

Communications effectiveness – what are we really measuring?

When pharma clients demand more effectiveness, do they really know what they want, asks Michel Nakache?

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

- PMLiVE

UK sets up digital innovation fund to improve patient care

NHS fund will also support new services that help share healthcare information

- PMLiVE

Medical communications 2.0

How social is medical communications?

UK reaffirms NHS access to NICE-approved drugs

Health Secretary makes pledge on same day Future Forum recommendations on NHS reform accepted

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links